CYP2C19 metabolizer phenotypes may affect the efficacy of statins on lowering small dense low-density lipoprotein cholesterol of patients with coronary artery disease

Ruozhu Dai, Xiaoyu Zhao, Huilin Zhuo, Wei Wang, Yue Xu, Zixin Hu, Tiexu Zhang, Jiangman ZhaoFrontiers in Cardiovascular Medicine 2022 · DOI

TL;DR

This study reveals that small dense LDL cholesterol (sdLDL-C) and a specific LDL subfraction (LDLC-4) are better indicators for coronary artery disease (CAD) risk than standard LDL-C. Furthermore, it demonstrates that an individual's genetic makeup, specifically their CYP2C19 metabolizer phenotype, can predict how effectively statin drugs will lower sdLDL-C levels.

What Problem Does This Paper Address?

Cardiovascular diseases, particularly those related to atherosclerosis, remain a leading cause of death globally. Dyslipidemia, characterized by abnormal lipid levels, is a major risk factor. While LDL-C is the primary target for lipid-lowering therapies, a significant number of patients with cardiovascular disease still have normal LDL-C levels, suggesting that standard markers may not be sufficient for comprehensive risk assessment and treatment monitoring. Small dense LDL cholesterol (sdLDL-C) has emerged as a potentially more sensitive biomarker, as it is considered more atherogenic. However, its clinical utility in risk screening and its response to statin therapy, especially in relation to genetic factors, requires further investigation. Additionally, CYP2C19 is a key enzyme in drug metabolism, and while its role in the metabolism of other drugs (like clopidogrel) is well-established, its impact on statin efficacy, particularly for sdLDL-C, has not been thoroughly explored. This paper aims to bridge these gaps by evaluating sdLDL-C and its subfractions for CAD risk prediction and investigating the influence of CYP2C19 genetic variations on statin efficacy in lowering sdLDL-C.

Methods

The study employed a case-control design, recruiting 182 patients with diagnosed coronary artery disease (CAD) and 200 healthy controls. Baseline laboratory tests were conducted to measure traditional blood lipids, glucose, and creatinine. A key methodological innovation was the separation and quantification of LDL-C subfractions. Genetic analysis was performed on CAD patients to determine polymorphisms in the SLCO1B1 and CYP2C19 genes. Following diagnosis, CAD patients were treated with statin drugs, and their LDL-C subfractions were re-evaluated after 3-6 months to assess the efficacy of the treatment. Statistical analyses included correlation tests (Spearman), logistic regression for risk factor identification, and Receiver Operating Characteristic (ROC) curve analysis to evaluate the diagnostic performance of different lipid markers. The impact of genetic polymorphisms on statin efficacy was analyzed by comparing changes in sdLDL-C levels among different CYP2C19 metabolizer phenotypes.

Datasets

The study utilized data from 182 patients with CAD and 200 non-CAD controls recruited from two hospitals in China. The dataset included clinical information (age, gender, BMI, smoking/drinking history, disease history) and laboratory indices (blood lipids, glucose, creatinine). LDL-C subfractions were measured before and after statin treatment for the CAD group. Genetic data for SLCO1B1 and CYP2C19 polymorphisms were collected from the CAD patients. No new benchmark datasets were introduced.

Key Insights and Ideas

  • sdLDL-C and LDLC-4 as superior CAD biomarkers: The study strongly suggests that sdLDL-C and specifically the LDLC-4 subfraction are more effective than standard LDL-C in identifying individuals at risk for CAD. This highlights the potential for refining lipid-based cardiovascular risk screening.
  • CYP2C19 genotype influences statin efficacy: A significant finding is that an individual's CYP2C19 metabolizer phenotype can predict how well statins will lower their sdLDL-C levels. This opens the door for personalized medicine approaches in lipid management.
  • SLCO1B1 genotype's limited impact on sdLDL-C efficacy: In contrast to CYP2C19, the study found no significant association between SLCO1B1 genotypes and the efficacy of statins in lowering sdLDL-C. This differentiates the genetic influence on statin response for different lipid fractions.

Key Results

  • CAD vs. Controls: Patients with CAD exhibited significantly higher levels of total cholesterol, LDL-C, and several LDL subfractions (LDLC-2 to LDLC-7), including sdLDL-C, compared to non-CAD controls.
  • Diagnostic Performance: sdLDL-C (AUC = 0.838) and LDLC-4 (AUC = 0.835) demonstrated superior performance in distinguishing CAD patients from controls compared to LDL-C (AUC = 0.658). Even after covariate adjustment, these markers maintained their strong discriminatory power.
  • CYP2C19 and Statin Efficacy: Patients with intermediate (IM) and poor (PM) CYP2C19 metabolizer phenotypes showed a significantly greater reduction in sdLDL-C levels after statin treatment compared to extensive (EM) metabolizers (P = 0.0268, FDR = 0.0536).
  • SLCO1B1 and Statin Efficacy: The SLCO1B1 genotype did not show a significant impact on the efficacy of statins in lowering sdLDL-C (adjusted P = 0.1611, FDR = 0.1611).

Limitations and Future Work

The authors acknowledge that the statistical power for the CYP2C19 analysis was moderate (0.57 with a sample size of 111), and the P-value was adjusted due to multiple testing. They emphasize the need for larger cohort studies to definitively validate the conclusion that CYP2C19 metabolizer phenotypes affect statin efficacy in lowering sdLDL-C. Future research could also explore the specific mechanisms by which CYP2C19 influences statin metabolism and sdLDL-C reduction, potentially leading to more targeted therapeutic strategies. Further investigation into the clinical utility of LDLC-4 as a primary screening tool for CAD is also warranted.

Summary updated

Abstract

sdLDL-C and LDLC-4 outperformed other blood lipids such as LDL-C for CAD risk screening. <i>CYP2C19</i> metabolizer phenotypes had the potential to predict the efficacy of statins in lowering sdLDL-C.
BibTeX
@inproceedings{dai2022cyp,
  author = {Ruozhu Dai and Xiaoyu Zhao and Huilin Zhuo and Wei Wang and Yue Xu and Zixin Hu and Tiexu Zhang and Jiangman Zhao},
  title = {{CYP2C19 metabolizer phenotypes may affect the efficacy of statins on lowering small dense low-density lipoprotein cholesterol of patients with coronary artery disease}},
  booktitle = {Frontiers in Cardiovascular Medicine},
  year = {2022},
  doi = {10.3389/fcvm.2022.1016126},
}
Figure